Cargando…
Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor–positive Breast Cancer
The high frequency of aberrant PI3K pathway activation in hormone receptor–positive (HR(+)) breast cancer has led to the development, clinical testing, and approval of the p110α-selective PI3K inhibitor alpelisib. The limited clinical efficacy of alpelisib and other PI3K inhibitors is partially attr...
Autores principales: | Jones, Robert B., Farhi, Jonathan, Adams, Miranda, Parwani, Kiran K., Cooper, Garrett W., Zecevic, Milica, Lee, Richard S., Hong, Andrew L., Spangle, Jennifer M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036132/ https://www.ncbi.nlm.nih.gov/pubmed/36970726 http://dx.doi.org/10.1158/2767-9764.CRC-22-0158 |
Ejemplares similares
-
H3.3K4M destabilizes enhancer H3K4 methyltransferases MLL3/MLL4 and impairs adipose tissue development
por: Jang, Younghoon, et al.
Publicado: (2019) -
Histone H3 E50K mutation confers oncogenic activity and supports an EMT phenotype
por: Sad, K, et al.
Publicado: (2023) -
The Histone Methyltransferase Activity of MLL1 Is Dispensable for Hematopoiesis and Leukemogenesis
por: Mishra, Bibhu P., et al.
Publicado: (2014) -
The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape
por: Wang, Lan-Hsin, et al.
Publicado: (2021) -
MLL3 and MLL4 Methyltransferases Bind to the MAFA and MAFB Transcription Factors to Regulate Islet β-Cell Function
por: Scoville, David W., et al.
Publicado: (2015)